Research & Discovery
Coval leverages its deep understanding of the local drug delivery systems to address critical unmet medical needs in chronic conditions. By advancing innovative therapies, Coval is transforming the treatment landscape with solutions that set new standards for efficacy and safety. Built on the proven success of established pharmaceutical active agents, Coval's proprietary MolecularX™ platform enables the development of highly differentiated and patient-centric molecules tailored for specific indications. These groundbreaking therapeutics are designed to deliver targeted, localized treatment while minimizing systemic side effects, offering the potential to improve the overall quality of life for patients worldwide.
Focusing On
• Targeted Solutions: Delivering localized treatments
• Innovative Therapies: Specializing in chronic disease care
• Advanced Platform: Customizing product design with precision
• Better Outcomes: Safer, more effective treatments
Pipeline
Zoom in
| Drug | Indication | Active Moiety | Administration | Development Phase |
| Lead | IND-enabling | Phase 1 | Phase 2 |
| CA0678 | Osteoarthritis | JAK inhibitor | IA injection | |
| CA7026 | Psoriasis | JAK inhibitor | Topical | |
| CA7026 | Hand Arthritis | JAK inhibitor | Topical | |
| CA9088 | wAMD | TKI | Intravitreal injection | |
| CA7026 | IBD | JAK inhibitor | Oral Capsule | |
MolecularX™, our molecular building block assembly
platform is a versatile technology designed to create first-in-class/best-in-class prodrugs from
existing marketed products. By integrating with local drug delivery technologies, this approach
optimizes therapeutic efficacy at the target site while minimizing systemic toxicity. Engineered linkers
ensure precise release of active payloads directly at diseased sites, offering a highly targeted and
innovative solution for advanced medical treatments.